Giugliano, R. P. Et Al. 2017. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA CARDIOLOGY , vol.2, no.12 , 1385-1391.

Giugliano, R. P., Keech, A., Murphy, S. A., Huber, K., TOKGÖZOĞLU, S. L., Lewis, B. S., ... Ferreira, J.(2017). Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA CARDIOLOGY , vol.2, no.12, 1385-1391.

Giugliano, Robert Et Al. "Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial," JAMA CARDIOLOGY , vol.2, no.12, 1385-1391, 2017

Giugliano, Robert P. Et Al. "Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial." JAMA CARDIOLOGY , vol.2, no.12, pp.1385-1391, 2017

Giugliano, R. P. Et Al. (2017) . "Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial." JAMA CARDIOLOGY , vol.2, no.12, pp.1385-1391.

@article{article, author={Robert P. Giugliano Et Al. }, title={Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial}, journal={JAMA CARDIOLOGY}, year=2017, pages={1385-1391} }